2025
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Scott Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. Npj Digital Medicine 2025, 8: 174. PMID: 40121304, PMCID: PMC11929913, DOI: 10.1038/s41746-025-01560-y.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapyBladder cancerPredicting response to neoadjuvant chemotherapyOptimal treatment strategyImprove patient survivalImproving clinical outcomesGene expression profilesBladder preservationPredictive biomarkersPatient survivalUnnecessary treatmentClinical outcomesTreatment responseRNA sequencingTumor heterogeneityTreatment strategiesClinical trialsGene signatureExpression profilesMolecular determinantsCancerChemotherapyBuilding accurate predictive modelsClinical Outcomes With Normothermic Pulsatile Organ Perfusion in Heart Transplantation: A Report From the OCS Heart Perfusion Registry
Stehlik J, Farr M, Mehra M, Schroder J, D’Alessandro D, Pal J, Villavicencio M, Gruber P, Couper G, Shudo Y, Patel P, Daneshmand M, Klein L, Shah A, Skipper E, Esmailian F, Goldstein D, Ohira S, Lozonschi L, Kaczorowski D, Takeda K, Malyala R, Haft J, Meyer D, Sun B, Pretorius V, Kilic A, Anyanwu A, Williams C, Pham D, Kai M, Sulemanjee N, Itoh A, Funamoto M, Salerno C, Ikonomidis J, Durham L, Shaffer A, Zhou X, Zafar F, Pinney S, Milano C. Clinical Outcomes With Normothermic Pulsatile Organ Perfusion in Heart Transplantation: A Report From the OCS Heart Perfusion Registry. Circulation 2025, 151: 896-909. PMID: 40052272, DOI: 10.1161/circulationaha.124.071743.Peer-Reviewed Original ResearchHeart transplantationStatic cold storageNormothermic regional perfusionPosttransplantation outcomesDCD donorsConsecutive heart transplantsRecipient characteristicsDBD donorsExtended-criteria donorsThoracoabdominal normothermic regional perfusionOrgan Care SystemPropensity score matchingClinical outcomesCost-effectiveness of angiographic quantitative flow ratio-guided coronary intervention: A multicenter, randomized, sham-controlled trial.
Zhao Y, Guan C, Wang Y, Jin Z, Yu B, Fu G, Chen Y, Guo L, Qu X, Zhang Y, Dou K, Wu Y, Yang W, Tu S, Escaned J, Fearon W, Qiao S, Cohen D, Krumholz H, Xu B, Song L. Cost-effectiveness of angiographic quantitative flow ratio-guided coronary intervention: A multicenter, randomized, sham-controlled trial. Chinese Medical Journal 2025 PMID: 40025631, DOI: 10.1097/cm9.0000000000003484.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioPercutaneous coronary interventionQuality-adjusted life yearsQuantitative flow ratioQFR-guided strategyClinical outcomesReduced rate of MACCEsChinese healthcare systemTwo-year clinical outcomesAngiography-based approachHealthcare systemAngiography-guided groupTwo-year follow-upRate of MACCEAngiography-guided strategyReference vessel diameterCardiovascular medication useCost-effectiveness ratioPost-myocardial infarctionFractional flow reserveTwo-year costsAngiography guidanceSham-controlled trialCost-utility analysisCerebrovascular eventsEVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaNational Cancer DatabaseMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalImpact of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsPrimary treatment typeCox proportional hazards analysisSite of metastasisEvaluate clinical outcomesProportional hazards analysisBorderline statistical significancePT0 rateOS benefitHistological subtypesCancer DatabaseClinical stageClinical outcomesTreatment patternsCurrent therapiesInstitutional experiencePrimary outcomeImpact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk
Yakubov S, Van Mieghem N, Oh J, Ito S, Grubb K, O’Hair D, Forrest J, Gada H, Mumtaz M, Deeb G, Tang G, Rovin J, Jain R, Windecker S, Skelding K, Kleiman N, Chetcuti S, Dedrick A, Boatman S, Popma J, Reardon M. Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk. Journal Of The American College Of Cardiology 2025 DOI: 10.1016/j.jacc.2025.02.009.Peer-Reviewed Original ResearchBioprosthetic valve dysfunctionRandomized controlled trialsRandomized controlled trial patientsClinical outcomesAssociated with increased 5-year all-cause mortalityWorsening heart failureContinued Access StudyAll-cause mortalityPost hoc analysisPooled randomized controlled trialsIntermediate riskPivotal trialsPrimary endpointAortic valve performanceValve dysfunctionSurgery patientsHeart failureValve diseaseTAVI patientsSupra-annularSurgeryCardiovascular mortalityClinical importancePatientsControlled trialsCarotid artery stenting with open versus closed stent cell configurations in the CREST-2 Registry
Lal B, Roubin G, Meschia J, Jones M, Heck D, Sternbergh W, Aronow H, Mena-Hurtado C, Howard G, Mayorga-Carlin M, Sorkin J, Brott T. Carotid artery stenting with open versus closed stent cell configurations in the CREST-2 Registry. Journal Of Vascular Surgery 2025 PMID: 40024381, DOI: 10.1016/j.jvs.2025.02.025.Peer-Reviewed Original ResearchCarotid artery stentingOpen-cell stentClosed-cell stentsFood and Drug Administration-approved deviceArtery stentingEmbolic protectionComparison of clinical outcomesStandardized procedure protocolsSymptomatic patientsPeri-proceduralAntiplatelet therapyPatient selectionClinical outcomesInstitutional experiencePatient characteristicsProcedural detailsCREST-2Lesion characteristicsLesion selectionHigh riskStentVascular anatomyPatient preferencesPatientsProcedure protocolEffect of Diabetes on Clinical Outcomes in Patients with Peripheral Arterial Disease undergoing Lower Extremity Revascularization: A Systematic Review and Meta-Analysis
Edjimbi J, Shah N, Kwaah P, Grimshaw A, Regan C, Nagpal S, Attaran R, Chaar C, Romain G, Smolderen K, Mena-Hurtado C. Effect of Diabetes on Clinical Outcomes in Patients with Peripheral Arterial Disease undergoing Lower Extremity Revascularization: A Systematic Review and Meta-Analysis. Journal Of Vascular Surgery 2025 PMID: 40015609, DOI: 10.1016/j.jvs.2025.02.018.Peer-Reviewed Original ResearchLower extremity revascularizationPeripheral arterial diseaseHospital readmissionRelative riskDiabetes mellitusRandom-effects meta-analysisIncreased riskMeta-analysisAssociation of DMExtremity revascularizationMortality riskWound infectionRisk estimatesAssociated with diabetes mellitusClinical outcomesSystematic reviewArtery diseaseSystematic searchObservational studyWound infection riskReadmissionEffects of diabetesAmputationRiskHospitalPresence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.
Hugaboom M, Wirth L, Street K, Ruthen N, Jegede O, Schindler N, Shah V, Zaemes J, El Ahmar N, Matar S, Savla V, Choueiri T, Denize T, West D, McDermott D, Plimack E, Sosman J, Haas N, Stein M, Alter R, Bilen M, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Cancer Discovery 2025, of1-of21. PMID: 39992403, DOI: 10.1158/2159-8290.cd-24-0991.Peer-Reviewed Original ResearchTertiary lymphoid structuresRenal cell carcinomaCD8+ T cellsAnti-PD1 monotherapyImmune checkpoint inhibitorsT cellsCell carcinomaLymphoid structuresClinical outcomesClinical response to PD-1 blockadeTreatment of advanced renal cell carcinomaResponse to PD-1 blockadePresence of tertiary lymphoid structuresAdvanced renal cell carcinomaTissue-resident T cellsPD-1 blockadePhase II clinical trialPD-1 pathwayCheckpoint inhibitorsICI resistancePD-1Responding patientsTumor microenvironmentTherapeutic responseTissue-residentClinical-genomic profiling of MDS to inform allo-HSCT: Recommendations from an international panel on behalf of the EBMT
Gurnari C, Robin M, Adès L, Aljurf M, Almeida A, Duarte F, Bernard E, Cutler C, Della Porta M, de Witte T, DeZern A, Drozd-Sokolowska J, Duncavage E, Fenaux P, Gagelmann N, Garcia-Manero G, Haferlach C, Haferlach T, Hasserjian R, Hellstrom-Lindberg E, Jacoby M, Kulasekararaj A, Lindsley R, Maciejewski J, Makishima H, Malcovati L, Mittelman M, Myhre A, Ogawa S, Onida F, Papaemmanuil E, Passweg J, Platzbecker U, Pleyer L, Raj K, Santini V, Sureda A, Tobiasson M, Voso M, Yakoub-Agha I, Zeidan A, Walter M, Kröger N, McLornan D, Cazzola M. Clinical-genomic profiling of MDS to inform allo-HSCT: Recommendations from an international panel on behalf of the EBMT. Blood 2025 PMID: 39970324, DOI: 10.1182/blood.2024025131.Peer-Reviewed Original ResearchAllo-HCTMolecular International Prognostic Scoring SystemGenomic profilingInternational Prognostic Scoring SystemAllogeneic hematopoietic cell transplantationAssociated with superior clinical outcomesMutant hematopoietic cellsNon-transplant therapiesPrognostic Scoring SystemHematopoietic cell transplantationClinical practiceTime of diagnosisSuperior clinical outcomesEstimate patient survivalIPSS-MAllo-HSCTCell transplantationExpert international panelPatient survivalPredisposition variantsTherapeutic optionsClinical outcomesCurative treatmentGenetic abnormalitiesHematopoietic cellsNatriuretic peptide testing in veterans hospitalized with heart failure: Potential differences by sex
Gandhi P, Runels T, Han L, Skanderson M, Bastian L, Brandt C, Hauser R, Feder S, Rodwin B, Farmer M, Bean-Mayberry B, Placide S, Gaffey A, Akgün K. Natriuretic peptide testing in veterans hospitalized with heart failure: Potential differences by sex. Heart & Lung 2025, 71: 25-31. PMID: 39970822, DOI: 10.1016/j.hrtlng.2025.02.001.Peer-Reviewed Original ResearchConceptsNatriuretic peptide testingHeart failure hospitalizationFacility characteristicsVeterans Affairs Healthcare SystemPeptide testingSex-based differencesFacility-related factorsSex-stratified modelsAssociated with increased likelihoodAssociated with decreased likelihoodHealthcare systemHF diagnosisEjection fractionCardiac comorbiditiesFailure hospitalizationClinical outcomesLogistic regressionAtrial fibrillationHeart failureVeteransClinical covariatesPatientsAdmissionSexAssociationDissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing
Castellanos-Rueda R, Wang K, Forster J, Driessen A, Frank J, Martínez M, Reddy S. Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing. Science Advances 2025, 11: eadp4008. PMID: 39951542, PMCID: PMC11827634, DOI: 10.1126/sciadv.adp4008.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorT-cell phenotypeT cell responsesT cell activationCAR T cell phenotypesCAR T-cell biologyModulate T cell responsesT cell persistenceCAR-T therapySingle-cell sequencingT cell functionT cell biologyCorrelated in vitroT therapyT cellsAntigen receptorClinical outcomesCD40 costimulationCancer treatmentPhenotypeSignaling domainMembrane-proximal domainCostimulationCD40Screening approachComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, jnumed.124.267927. PMID: 39947910, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsInpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.
Riaz F, Vaughn J, Zhu H, Dickerson J, Sayegh H, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Cohen R, Parikh R, Reuss J, Prsic E, Doroshow D. Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis. JCO Oncology Practice 2025, op2400788. PMID: 39937997, DOI: 10.1200/op-24-00788.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsOverall survivalICI administrationSolid malignanciesPatients treated with immune checkpoint inhibitorsAdministration of immune checkpoint inhibitorsMultivariate Cox proportional hazards model analysisResponse to ICI therapyCox proportional hazards model analysisProportional hazards model analysisAdvanced solid malignanciesKaplan-Meier methodOutcomes of patientsInstitutional electronic medical recordsHazards model analysisCox proportional hazards modelsProportional hazards modelCheckpoint inhibitorsICI therapyMedian OSICI initiationICI useRetrospective studyClinical outcomesClinicodemographic variablesDose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study.
Agarwal R, Ebrahimi H, Zengin Z, Barragán Carrillo R, Dizman N, Zugman M, Jaime-Casas S, Meza L, Li X, Hsu J, Castro D, Mercier B, Lee P, Takahashi M, Tripathi A, Dorff T, Caporaso G, Lee K, Pal S, Chehrazi-Raffle A. Dose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study. Journal Of Clinical Oncology 2025, 43: tps611-tps611. DOI: 10.1200/jco.2025.43.5_suppl.tps611.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsProgression-free survivalMaximum tolerated dosePhase I studyRenal cell carcinomaDose levelsCell carcinomaClinical outcomesEfficacy of immune checkpoint inhibitorsMetastatic renal cell carcinoma patientsModulation of immune pathwaysImmune checkpoint inhibitor therapyStandard-of-care treatmentIMDC risk groupsPlanned dose levelsCombination of nivolumabDose-limiting toxicityDose-escalation designDose-escalation studyECOG performance statusDose-finding studyGut microbiomeCheckpoint inhibitorsDose escalationRisk factors for cut-throughs in intertrochanteric hip fracture fixation Tip-Apex Distance (TAD) <10 mm and Apex-to-Center <4 mm
Levine A, Klug T, Cross J, Salameh M, Riedel M, Leslie M. Risk factors for cut-throughs in intertrochanteric hip fracture fixation Tip-Apex Distance (TAD) <10 mm and Apex-to-Center <4 mm. Injury 2025, 56: 112205. PMID: 39954635, DOI: 10.1016/j.injury.2025.112205.Peer-Reviewed Original ResearchConceptsTip-apex distanceIntertrochanteric hip fracturesHip fractureRisk factorsAnterior-posteriorLevel 1 academic trauma centerSliding hip screwFracture reduction qualityNeck-shaft angleCut-out complicationsTrauma centerHip screwNeck-shaftIntramedullary nailingRetrospective reviewReduction qualityReduced riskIncreased riskFracture typeClinical outcomesRiskComplicationsCohortLateral viewFixation devicesRetrospective Visual and Quantitative Assessment of Burst Suppression With and Without Identical Bursts in Patients After Cardiac Arrest
Fong M, Pu K, Beekman R, Kim N, Nguyen C, Gilmore E, Hirsch L, Zaveri H. Retrospective Visual and Quantitative Assessment of Burst Suppression With and Without Identical Bursts in Patients After Cardiac Arrest. Neurocritical Care 2025, 1-11. PMID: 39900751, DOI: 10.1007/s12028-024-02208-7.Peer-Reviewed Original ResearchIdentical burstsBurst suppressionCardiac arrest survivorsInterburst intervalClinical featuresNeurological outcomeCardiac arrestArrest survivorsAssociated with poor neurological outcomeContinuous electroencephalogramCerebral Performance Category scoreAssociated with poor outcomesCardiac arrest patientsPoor neurological outcomePost-cardiac arrestPredictors of mortalityUS academic medical centersEEG backgroundPrognostic significanceArrest patientsClinical outcomesPoor outcomeRetrospective analysisAcademic medical centerUS cohortPodium Presentation Title: Arthroscopic Management of Talus Fracture: A Review of the Clinical Outcomes and Surgical Technique
Tornberg H, Hartman H, Fine-Lease P, Gianakos A. Podium Presentation Title: Arthroscopic Management of Talus Fracture: A Review of the Clinical Outcomes and Surgical Technique. Arthroscopy The Journal Of Arthroscopic And Related Surgery 2025, 41: e17-e18. DOI: 10.1016/j.arthro.2024.11.039.Peer-Reviewed Original ResearchWorse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation
Makarova E, Fan X, Farooqi I, Bakhl K, Murphy T, Stonesifer E, Faust A. Worse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation. Journal Of Liver Transplantation 2025, 17: 100257. DOI: 10.1016/j.liver.2024.100257.Peer-Reviewed Original ResearchTrans arterial chemoembolizationDecompensated liver functionHepatocellular carcinomaLiver functionLiver transplantationClinical outcomesRetrospective cohort study of patientsClinical outcomes of patientsWorsening of liver functionCohort study of patientsCompensated liver functionOutcomes of patientsCohort of patientsRetrospective cohort studyStudy of patientsStatistically significant differenceLocoregional therapyArterial chemoembolizationDecompensated cirrhosisPoor outcomePrimary statistical analysisPatientsCirrhosisTransplantationSignificant differenceEndovascular Repair vs Medical Therapy for Uncomplicated Acute Type B Dissection: Aortic Remodeling
Higaki A, Hameed I, Erez E, Hu K, Asmelash S, Chatterjee D, Shou B, Zafar M, Assi R, Vallabhajosyula P. Endovascular Repair vs Medical Therapy for Uncomplicated Acute Type B Dissection: Aortic Remodeling. Annals Of Thoracic Surgery Short Reports 2025 DOI: 10.1016/j.atssr.2025.01.012.Peer-Reviewed Original ResearchUncomplicated acute type B aortic dissectionThoracic endovascular aortic repairOptimal medical therapyMedical therapyAortic remodelingAortic levelsClinical outcomesClinical outcomes of thoracic endovascular aortic repairLumen diameterPatients treated with thoracic endovascular aortic repairOutcomes of thoracic endovascular aortic repairUncomplicated acute type B dissectionAcute type B aortic dissectionOMT patientsAcute type B dissectionType B aortic dissectionFavorable aortic remodelingOptimal initial managementInitial treatment modalityMedian follow-upType B dissectionEndovascular aortic repairB aortic dissectionFalse lumen thrombosisLeft subclavian arteryP-551. The Effects of Antiretroviral Therapy on Immune Activation, Inflammation, Cellular Changes and Clinical Outcomes in Elite Controllers
Chan E, Zhou L, Emu B, Paintsil E, Barakat L. P-551. The Effects of Antiretroviral Therapy on Immune Activation, Inflammation, Cellular Changes and Clinical Outcomes in Elite Controllers. Open Forum Infectious Diseases 2025, 12: ofae631.750. PMCID: PMC11777457, DOI: 10.1093/ofid/ofae631.750.Peer-Reviewed Original ResearchEffects of antiretroviral therapyAntiretroviral therapyElite controllersViral loadIL-6Inflammatory markersImmune activationReactive oxygen speciesReactive oxygen species productionAdverse effects of ARTMitochondrial membrane potentialBenefits of antiretroviral therapyAntiretroviral Therapy ToxicitiesInflammatory markers IL-6Antiretroviral therapy groupHIV viral loadMembrane potentialCurrent published dataUtilization of antiretroviral therapyCellular inflammatory markersCompared to baselineViremic controllersClinical outcomesCRP decreaseLevels of mtDNA deletions
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply